Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Treatment options for younger patients with newly diagnosed AML are expanding, with the recent approvals of several targeted therapies, as well as clinical trials investigating novel agents. In this interview, Dr. Pinkal Desai discusses the diagnosis and prognosis of younger people with AML, current standards of care, and key data from clinical trials assessing novel targeted combination therapies to optimize the management of this unique patient population.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical needs resulting from current standards of care in newly diagnosed AML
  • Summarize data supporting the role of novel combination therapies in newly diagnosed AML

Agenda

Novel Therapeutic Approaches in Newly Diagnosed Younger Patients with AML – Pinkal Desai, MD, MPH

Instructions for Participation and Credit

This activity is eligible for credit through November 30, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Pinkal Desai, MD, MPH
Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
New York-Presbyterian Hospital
New York, New York

Dr. Pinkal Desai received her MBBS at Byram Jeejeebhoy Medical College in India, and her MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in hematology-medical oncology at Providence Hospital Medical Center, serving as chief fellow. Dr. Desai is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the New York-Presbyterian Hospital. She was recruited to serve in the Leukemia Program to develop a clinical practice devoted to leukemia, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) where she will also develop the clinical and translational research protocols and projects.

Dr. Desai is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has served on the ASCO University Committee. She has been published in Cancer Epidemiology Biomarkers Prevention and International Journal of Molecular Epidemiology and Genetics. In addition, Dr. Desai is the lead author and co-author on numerous Women’s Health Initiative (WHI) paper proposals and has presented abstracts at national meetings.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-047-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Pinkal Desai has received honoraria related to formal advisory activities from Agios, argenx, and Cellerant Therapeutics, Inc., as well as consultant fees from Cellerant.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.